TARIFFS LATEST

US, China to slash tariffs for 90 days

Cboe UK GBp

AstraZeneca PLC (AZNL.XC)

9,913.00

-301.00

(-2.95%)

As of 1:25:36 PM GMT+1. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for AZNL.XC

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial

AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial

Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices

Trump's Plan to Cut Drug Prices Hits Pharma Stocks

Trump's Plan to Cut Drug Prices Hits Pharma Stocks

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment